Conditions: Obesity
Keywords: pre-diabetes isotopes insulin secretion insulin action GLP-1 simple obesity impaired fasting glucose
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 26
Healthy volunteers: yes

Brief summary:
Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to abnormal EGP and insulin secretion in people with impaired fasting glucose (IFG) was the objective of the current study. The investigators hypothesized that defects in GLP-1 may explain the inappropriate basal EGP and diminished insulin secretion in IFG, and, furthermore, that by increasing circulating GLP-1 levels (using a new medicine called "sitagliptin") the investigators could reverse these defects.

Detailed description:

Arms:
arm 1: Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate) arm 2: Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)

Interventions: intervention 1: Sitagliptin Phosphate
Intervention descriptions: intervention 1: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made

Protocol document: